Detalle Publicación

Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop

Título de la revista: CANCER RESEARCH
ISSN: 0008-5472
Volumen: 76
Número: 10
Páginas: 2863 - 2867
Fecha de publicación: 2016
The recent approval by the FDA of the combination of anti-CTLA4 and anti-PD-1 mAbs for the treatment of BRAF-unmutated unresectable or metastatic melanoma is a landmark for the development of cancer immunotherapy. On October 18 to 22, 2015, a symposium was held in Pamplona (Spain) to present and discuss the basic and clinical discoveries that have brought us to this milestone and to explore other targets and immunotherapy strategies aimed at attaining more efficacious oncology practice in the short term.